We are live on ! Find out more
BAX icon

Baxter International

25.74 USD
-0.60
2.28%
At close Updated Nov 12, 4:00 PM EST
Pre-market
After hours
25.70
-0.04
0.16%
1 day
-2.28%
5 days
3%
1 month
3.87%
3 months
-4.49%
6 months
43.88%
Year to date
32%
1 year
37.65%
5 years
-67.61%
10 years
-42.83%
 

About: Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Employees: 37,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 47.6%
Neutral 42.9%
Negative 9.5%
Positive
MarketBeat
13 days ago
What Baxter International (BAX) Said on Its Q3 Earnings Call
Baxter International NYSE: BAX raised its full-year 2026 outlook after reporting third-quarter sales and adjusted earnings that exceeded its expectations, citing broad-based growth across its portfolio, improving execution and strong free cash flow generation.
What Baxter International (BAX) Said on Its Q3 Earnings Call
Positive
Zacks Investment Research
14 days ago
Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised
BAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.
Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised
Neutral
Seeking Alpha
14 days ago
Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
Negative
Benzinga
14 days ago
Why Is Baxter Stock Trading Lower on Thursday?
Baxter International Inc. (NYSE:BAX) on Thursday reported better-than-expected third-quarter financial results and raised its fiscal 2026 guidance.
Why Is Baxter Stock Trading Lower on Thursday?
Positive
Zacks Investment Research
14 days ago
Compared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics
Positive
Zacks Investment Research
14 days ago
Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates
Baxter International (BAX) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.69 per share a year ago.
Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates
Neutral
Business Wire
14 days ago
Baxter Reports Third-Quarter 2026 Results
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2026. “We delivered a strong third quarter, with growth across all segments and divisions globally,” said Andrew Hider, president and CEO. “We continue to make steady progress stabilizing the business, strengthening the balance sheet and driving continuous improvement. Our results reinforce our confidence in this direction as we build a stronger founda.
Baxter Reports Third-Quarter 2026 Results
Positive
Zacks Investment Research
17 days ago
Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?
Baxter International Inc. BAX is scheduled to release third-quarter 2026 results on Oct. 29, before the opening bell. In the last reported quarter, the company's earnings beat the Zacks Consensus Estimate by 55.6%.
Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?
Negative
Zacks Investment Research
21 days ago
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
Positive
Seeking Alpha
1 month ago
Baxter International: The Vantive Transition Complicates Margin Recovery
Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.
Baxter International: The Vantive Transition Complicates Margin Recovery
Price charts implemented using Lightweight Charts™